ArticleJournal of translational medicine2026
Exosomal miR-21 mitigates pulmonary hypertension-induced right-heart remodeling by preserves mitochondrial homeostasis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleRight ventricular (RV) dysfunction is the principal determinant of prognosis in pulmonary arterial hypertension (PAH), yet the molecular mediators linking pulmonary vascular stress to RV remodeling remain incompletely understood. Exosomal microRNAs (miRNAs) have emerged as paracrine messengers capable of mediating inter-organ communication. This study investigated the role of exosomal miR-21 in pulmonary vascular–RV cross-talk in PAH.
methodsExosomes were isolated from right-heart catheterization samples of PAH patients and analyzed by next-generation sequencing to identify enriched miRNAs. Functional studies were performed using hypoxia-stimulated human pulmonary microvascular endothelial cells (HMECs)-derived exosomes applied to cardiomyocytes. In vivo validation included Sugen/hypoxia (SuHx)-induced PAH in wild-type and miR-21 knockout (miR-21−/−) mice, complemented by parabiosis experiments to test systemic exosomal transfer.
resultsExosomal miR-21 was markedly enriched in the pulmonary circulation of PAH patients. Hypoxia upregulated miR-21 in HMECs-derived exosomes, which were internalized by cardiomyocytes, reducing apoptosis and protecting against mitochondrial dysfunction via SPRY2/p-ERK and PTEN/AKT signaling. In SuHx models, miR-21−/− mice developed more severe RV remodeling, fibrosis, and mitochondrial gene suppression. Parabiosis demonstrated that wild-type partners conferred RV protection to miR-21−/− mice with an increasing expression of miR-21 and attenuated pulmonary arterial pressure and remodeling, whereas miR-21−/− pairs exhibited exacerbated RV impairment.
conclusionsEndothelial-derived exosomal miR-21 is upregulated by hypoxia and associated with cardioprotective effects by limiting apoptosis and mitochondrial dysfunction in adjacent cardiomyocytes. These findings identify exosomal miR-21 as a key mediator associated with RV adaptation and support its potential as a biomarker and therapeutic target in PAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.